Lupin Strengthens Rare Disease Portfolio with EMA Approval for Pediatric Use of NaMuscla

Lupin has secured a key regulatory approval from the European Medicines Agency (EMA), expanding the use of its rare disease drug NaMuscla to pediatric patients with non-dystrophic myotonic disorders (NDM). The approval adds two new capsule strengths 62 mg and 83 mg, to the existing 167 mg dosage, allowing treatment to be better tailored across different age groups. NaMuscla is now approved for children aged 6–11 years weighing at least 20 kg, adolescents aged 12–17 years, and adults for the symptomatic treatment of myotonia, a rare inherited neuromuscular disorder that causes muscles to remain stiff after movement. With limited treatment options available for children suffering from this lifelong condition, the expanded approval is expected to improve patient access across Europe while reinforcing Lupin's presence in the specialty and rare disease therapy market. $LUPIN Disclaimer: This post is for informational purposes only and not a recommendation to buy or sell any securities. I, or my family, associates, or relatives, may have a financial interest in the securities mentioned.